MGO Private Wealth LLC Purchases New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

MGO Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, Holdings Channel reports. The firm acquired 511 shares of the medical research company’s stock, valued at approximately $297,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oliver Luxxe Assets LLC lifted its position in shares of Thermo Fisher Scientific by 0.5% in the 1st quarter. Oliver Luxxe Assets LLC now owns 8,958 shares of the medical research company’s stock worth $5,207,000 after purchasing an additional 44 shares during the period. Diversified Trust Co grew its holdings in Thermo Fisher Scientific by 3.2% in the first quarter. Diversified Trust Co now owns 8,976 shares of the medical research company’s stock worth $5,217,000 after purchasing an additional 282 shares during the last quarter. Aviance Capital Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 20.9% during the 1st quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock valued at $7,581,000 after purchasing an additional 2,251 shares during the last quarter. Roberts Wealth Advisors LLC purchased a new position in Thermo Fisher Scientific during the 1st quarter worth $4,422,000. Finally, Financial Partners Group LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth about $241,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.0 %

Shares of TMO stock traded down $11.28 on Monday, hitting $541.72. 1,458,613 shares of the stock traded hands, compared to its average volume of 1,548,049. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The stock has a market capitalization of $206.79 billion, a PE ratio of 35.47, a PEG ratio of 2.58 and a beta of 0.77. The firm’s 50-day moving average price is $574.84 and its two-hundred day moving average price is $563.36. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TMO. Jefferies Financial Group reaffirmed a “buy” rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Barclays lowered their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft lifted their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, Robert W. Baird reduced their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $607.06.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,000 shares of company stock worth $12,532,780. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.